• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Chronic Opioid Use Linked to Higher Healthcare Spending, Hospital Stays, AJAC Study Finds


Amid public health concerns about the risks of opioid overuse, a recent study in The American Journal of Accountable Care® (AJAC) shows increased economic burden on patients and payers when opioid therapy for noncancer pain continues beyond the initial prescription.

(CRANBURY, N.J. — December 13, 2018) - Using data from commercial insurance claims of working-aged adults, new research published in the December issue of The American Journal of Accountable Care® (AJAC) found that chronic opioid therapy (COT) for noncancer pain is associated with increased healthcare spending as well as hospital stays. The insights from the study, “Increased Healthcare Utilization and Expenditures Associated With Chronic Opioid Therapy,” can be used by payers to intervene after opioids are prescribed but before patients transition to long-term use.

Patients who transitioned to COT, which is defined as daily or near-daily use of opioids for at least 90 days, had total healthcare expenditures that were $4607 higher than those of patients who did not continue long-term opioid use. Total expenditures, without prescription drugs, were defined as the sum of emergency department, inpatient, physician, and other spending. Inpatient spending alone among the COT group was $2453 higher than that of patients who did not transition to COT.

The sample—derived from a random sample of commercial enrollees that was released under licensing from the IQVIA Real-World Data Adjudicated Claims database—comprised 3776 adults aged 28 to 63 years in the COT group and 16,425 adults in the non-COT group.

With approximately 126 million Americans experiencing some type of pain in the past 3 months, payers, government agencies, and medical associations are trying to encourage nonopioid therapies for chronic noncancer pain. In 2017, opioid-related deaths surged past 72,000, with the increase driven by synthetic opioids.

“Any intervention focused on curbing transition to COT has the potential to prevent inpatient use and can lead to cost savings for the payer(s),” the study noted, adding that reducing inpatient utilization benefits patients via improved quality of life and lower out-of-pocket costs.

The authors, two of whom received funding from the National Institutes of Health, did not include in their study information on types of pain, response to pain treatment, socioeconomic status, and other factors.

“We hope that these findings can help lay the foundation, including financial justification, for prevention programs related to identifying and curbing inappropriate chronic opioid use,” said lead author Douglas Thornton, PharmD, PhD, of the College of Pharmacy at University of Houston.

AJAC, a quarter-yearly sister publication of The American Journal of Managed Care® (AJMC®), is dedicated to providing a platform for healthcare professionals and organizations to share research and best practices in the realm of accountable care.

For more information, visit www.ajmc.com.

About  The American Journal of Managed Care®

The American Journal of Managed Care® (AJMC®) is a peer-reviewed, Medline-indexed journal that keeps readers on the forefront of health policy by publishing research relevant to industry decision makers as they work to promote the efficient delivery of high-quality care. AJMC.com is the essential website for managed care professionals, distributing industry updates daily to leading stakeholders. Other titles in the AJMC® family include The American Journal of Accountable Care® and two evidence-based series, Evidence-Based Oncology and Evidence-Based Diabetes Management. These comprehensive offerings bring together stakeholder views from payers, providers, policymakers and other industry leaders in managed care. To order reprints of articles appearing in AJMC® publications, please contact Gil Hernandez at 609-716-7777, ext. 139.

AJMC® Media Contacts

Alexandra Ventura, 609-716-7777, ext. 121


John Patricolo, 609-325-4630, ext. 133


Related Content
© 2024 MJH Life Sciences
All rights reserved.